Clinical characteristics of seven patients with lanthanum phosphate deposition in the stomach

Naoko Murakami, Masao Yoshioka, Masaya Iwamuro, Junichirou Nasu, Soichiro Nose, Junji Shiode, Hiroyuki Okada, Kazuhide Yamamoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective To analyze the clinical characteristics and endoscopic features of patients with lanthanum deposition in the stomach. Patients We retrospectively reviewed seven patients with lanthanum deposition in the stomach who were diagnosed at Okayama Saiseikai General Hospital. We investigated the patient sex, age at diagnosis, medical and medication histories, gastrointestinal symptoms, complications, presence or absence of gastric atrophy, and outcome. We also investigated any changes in the endoscopic features if previous endoscopic images were available. Results Seven patients (six males and one female) had lanthanum deposition. The median age was 65 years (range, 50-79 years). All patients had been undergoing dialysis (continuous ambulatory peritoneal dialysis in one patient, hemodialysis in six patients). The dialysis period ranged from 16 to 73 months (median, 52 months). The patients had all been taking lanthanum carbonate for a period ranging from 5 to 45 months (median, 27 months). Gastric atrophy was noted in 6 patients (85.7%). One patient had difficulty swallowing, and 1 other patient had appetite loss. The other 5 patients were asymptomatic. Endoscopic features included annular whitish mucosa (n = 4), diffuse whitish mucosa (n = 3), and whitish spots (n = 2). Five patients underwent multiple esophagogastroduodenoscopy. The endoscopic features were unchanged in 2 patients, whereas the whitish mucosa became apparent and spread during the course in 3 patients. Conclusion We identified 7 patients with lanthanum deposition in the stomach. All patients showed whitish lesions macroscopically. Although the pathogenicity of gastric lanthanum deposition is uncertain, lanthanum-related lesions in the stomach progressed during continuous lanthanum phosphate intake in several patients.

Original languageEnglish
Pages (from-to)2089-2095
Number of pages7
JournalInternal Medicine
Volume56
Issue number16
DOIs
Publication statusPublished - 2017

Fingerprint

Lanthanum
Stomach
Phosphates
Mucous Membrane
Atrophy
Dialysis
Digestive System Endoscopy

Keywords

  • Chronic kidney disease
  • Hyperphosphatemia
  • Lanthanum carbonate

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Clinical characteristics of seven patients with lanthanum phosphate deposition in the stomach. / Murakami, Naoko; Yoshioka, Masao; Iwamuro, Masaya; Nasu, Junichirou; Nose, Soichiro; Shiode, Junji; Okada, Hiroyuki; Yamamoto, Kazuhide.

In: Internal Medicine, Vol. 56, No. 16, 2017, p. 2089-2095.

Research output: Contribution to journalArticle

Murakami, Naoko ; Yoshioka, Masao ; Iwamuro, Masaya ; Nasu, Junichirou ; Nose, Soichiro ; Shiode, Junji ; Okada, Hiroyuki ; Yamamoto, Kazuhide. / Clinical characteristics of seven patients with lanthanum phosphate deposition in the stomach. In: Internal Medicine. 2017 ; Vol. 56, No. 16. pp. 2089-2095.
@article{2dc554da5ab84ef99ba18249b87cbfbc,
title = "Clinical characteristics of seven patients with lanthanum phosphate deposition in the stomach",
abstract = "Objective To analyze the clinical characteristics and endoscopic features of patients with lanthanum deposition in the stomach. Patients We retrospectively reviewed seven patients with lanthanum deposition in the stomach who were diagnosed at Okayama Saiseikai General Hospital. We investigated the patient sex, age at diagnosis, medical and medication histories, gastrointestinal symptoms, complications, presence or absence of gastric atrophy, and outcome. We also investigated any changes in the endoscopic features if previous endoscopic images were available. Results Seven patients (six males and one female) had lanthanum deposition. The median age was 65 years (range, 50-79 years). All patients had been undergoing dialysis (continuous ambulatory peritoneal dialysis in one patient, hemodialysis in six patients). The dialysis period ranged from 16 to 73 months (median, 52 months). The patients had all been taking lanthanum carbonate for a period ranging from 5 to 45 months (median, 27 months). Gastric atrophy was noted in 6 patients (85.7{\%}). One patient had difficulty swallowing, and 1 other patient had appetite loss. The other 5 patients were asymptomatic. Endoscopic features included annular whitish mucosa (n = 4), diffuse whitish mucosa (n = 3), and whitish spots (n = 2). Five patients underwent multiple esophagogastroduodenoscopy. The endoscopic features were unchanged in 2 patients, whereas the whitish mucosa became apparent and spread during the course in 3 patients. Conclusion We identified 7 patients with lanthanum deposition in the stomach. All patients showed whitish lesions macroscopically. Although the pathogenicity of gastric lanthanum deposition is uncertain, lanthanum-related lesions in the stomach progressed during continuous lanthanum phosphate intake in several patients.",
keywords = "Chronic kidney disease, Hyperphosphatemia, Lanthanum carbonate",
author = "Naoko Murakami and Masao Yoshioka and Masaya Iwamuro and Junichirou Nasu and Soichiro Nose and Junji Shiode and Hiroyuki Okada and Kazuhide Yamamoto",
year = "2017",
doi = "10.2169/internalmedicine.8720-16",
language = "English",
volume = "56",
pages = "2089--2095",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "16",

}

TY - JOUR

T1 - Clinical characteristics of seven patients with lanthanum phosphate deposition in the stomach

AU - Murakami, Naoko

AU - Yoshioka, Masao

AU - Iwamuro, Masaya

AU - Nasu, Junichirou

AU - Nose, Soichiro

AU - Shiode, Junji

AU - Okada, Hiroyuki

AU - Yamamoto, Kazuhide

PY - 2017

Y1 - 2017

N2 - Objective To analyze the clinical characteristics and endoscopic features of patients with lanthanum deposition in the stomach. Patients We retrospectively reviewed seven patients with lanthanum deposition in the stomach who were diagnosed at Okayama Saiseikai General Hospital. We investigated the patient sex, age at diagnosis, medical and medication histories, gastrointestinal symptoms, complications, presence or absence of gastric atrophy, and outcome. We also investigated any changes in the endoscopic features if previous endoscopic images were available. Results Seven patients (six males and one female) had lanthanum deposition. The median age was 65 years (range, 50-79 years). All patients had been undergoing dialysis (continuous ambulatory peritoneal dialysis in one patient, hemodialysis in six patients). The dialysis period ranged from 16 to 73 months (median, 52 months). The patients had all been taking lanthanum carbonate for a period ranging from 5 to 45 months (median, 27 months). Gastric atrophy was noted in 6 patients (85.7%). One patient had difficulty swallowing, and 1 other patient had appetite loss. The other 5 patients were asymptomatic. Endoscopic features included annular whitish mucosa (n = 4), diffuse whitish mucosa (n = 3), and whitish spots (n = 2). Five patients underwent multiple esophagogastroduodenoscopy. The endoscopic features were unchanged in 2 patients, whereas the whitish mucosa became apparent and spread during the course in 3 patients. Conclusion We identified 7 patients with lanthanum deposition in the stomach. All patients showed whitish lesions macroscopically. Although the pathogenicity of gastric lanthanum deposition is uncertain, lanthanum-related lesions in the stomach progressed during continuous lanthanum phosphate intake in several patients.

AB - Objective To analyze the clinical characteristics and endoscopic features of patients with lanthanum deposition in the stomach. Patients We retrospectively reviewed seven patients with lanthanum deposition in the stomach who were diagnosed at Okayama Saiseikai General Hospital. We investigated the patient sex, age at diagnosis, medical and medication histories, gastrointestinal symptoms, complications, presence or absence of gastric atrophy, and outcome. We also investigated any changes in the endoscopic features if previous endoscopic images were available. Results Seven patients (six males and one female) had lanthanum deposition. The median age was 65 years (range, 50-79 years). All patients had been undergoing dialysis (continuous ambulatory peritoneal dialysis in one patient, hemodialysis in six patients). The dialysis period ranged from 16 to 73 months (median, 52 months). The patients had all been taking lanthanum carbonate for a period ranging from 5 to 45 months (median, 27 months). Gastric atrophy was noted in 6 patients (85.7%). One patient had difficulty swallowing, and 1 other patient had appetite loss. The other 5 patients were asymptomatic. Endoscopic features included annular whitish mucosa (n = 4), diffuse whitish mucosa (n = 3), and whitish spots (n = 2). Five patients underwent multiple esophagogastroduodenoscopy. The endoscopic features were unchanged in 2 patients, whereas the whitish mucosa became apparent and spread during the course in 3 patients. Conclusion We identified 7 patients with lanthanum deposition in the stomach. All patients showed whitish lesions macroscopically. Although the pathogenicity of gastric lanthanum deposition is uncertain, lanthanum-related lesions in the stomach progressed during continuous lanthanum phosphate intake in several patients.

KW - Chronic kidney disease

KW - Hyperphosphatemia

KW - Lanthanum carbonate

UR - http://www.scopus.com/inward/record.url?scp=85027579196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027579196&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.8720-16

DO - 10.2169/internalmedicine.8720-16

M3 - Article

VL - 56

SP - 2089

EP - 2095

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 16

ER -